Skip to main content
SpringerLink
Log in

Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

A 41 year old female with type I cryoglobulinemia, refractory to methylprednisolone, rituximab, and cyclophosphamide complicated by a rising serum viscosity was treated with alemtuzumab. After a cumulative dose of 1,085 mg of alemtuzumab, her serum viscosity decreased to normal. Treatment toxicity was limited to fungal esophagitis responsive to topical therapy. This case demonstrates the potential use of alemtuzumab in the treatment of refractory cryoglobulinemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kallemuchikkal U, Gorevic PD (1999) Evaluation of cryoglobulins. Arch Pathol Lab Med 123:119–125

    PubMed  CAS  Google Scholar 

  2. Gertz MA, Anagnostopoulos A, Anderson K, Branagan AR, Coleman M, Frankel SR, Giralt S, Levine T, Munshi N, Pestronk A, Rajkumar V, Treon SP (2003) Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 30:121–126

    Article  PubMed  Google Scholar 

  3. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T (2005) Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford) 44:410–411

    Article  CAS  Google Scholar 

  4. Gladstone DE, Golightly MG, Zamkoff KW (2005) Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil. Rheumatol Int 25:635–636

    Article  PubMed  Google Scholar 

  5. Nuckel H, Frey UH, Roth A, Duhrsen U, Siffert W (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 514:217–224

    PubMed  Google Scholar 

  6. Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, Johansson E, Mellstedt H, Lundin J, Osterborg A (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 20(12):2204–2207

    Article  PubMed  CAS  Google Scholar 

  7. Cheung WW, Hwang GY, Tse E, Kwong YL (2006) Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 91:ECR13

    PubMed  Google Scholar 

  8. Stasi R, Provan D (2004) Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 79:504–522

    Article  PubMed  Google Scholar 

  9. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16–24

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stony Brook University Medical Center, SUNY Stony Brook, HSC, Level 17, Rm 080, Stony Brook, NY, 11794-8174, USA

    David Chu & Michelle Stevens

  2. Hematology Oncology Associates of Western Suffolk, 24 East Main Street, Sky Shore, NY, 11706, USA

    Douglas Edward Gladstone

Authors
  1. David Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Stevens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Edward Gladstone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Edward Gladstone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chu, D., Stevens, M. & Gladstone, D.E. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int 27, 1173–1175 (2007). https://doi.org/10.1007/s00296-007-0354-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-007-0354-1

Keywords

Search

Navigation